UpToDate
Official reprint from UpToDate®
www.uptodate.com ©2016 UpToDate®

Clinical presentation, diagnosis, and staging evaluation of neuroblastoma

Authors
Jason M Shohet, MD, PhD
Jed G Nuchtern, MD, FACS, FAAP
Section Editor
Julie R Park, MD
Deputy Editor
Sadhna R Vora, MD

INTRODUCTION

The term neuroblastoma is commonly used to refer to a spectrum of neuroblastic tumors (including neuroblastomas, ganglioneuroblastomas, and ganglioneuromas) that arise from primitive sympathetic ganglion cells and, like paragangliomas and pheochromocytomas, have the capacity to synthesize and secrete catecholamines. (See "Paragangliomas: Epidemiology, clinical presentation, diagnosis, and histology" and "Clinical presentation and diagnosis of pheochromocytoma".)

Neuroblastomas, which account for 97 percent of all neuroblastic tumors, are heterogeneous, varying in terms of location, histopathologic appearance, and biologic characteristics [1]. They are most remarkable for their broad spectrum of clinical behavior, which can range from spontaneous regression, to maturation to a benign ganglioneuroma, or aggressive disease with metastatic dissemination leading to death [2].

Clinical diversity correlates closely with numerous clinical and biological factors (including patient age, tumor stage and histology, and genetic and chromosomal abnormalities). For example, most infants with disseminated disease have a favorable outcome following treatment with chemotherapy and surgery, although the majority of children older than one year of age with advanced-stage disease die from progressive disease despite intensive multimodality therapy. This clinical complexity likely derives from the developmental origins of neuroblastoma, which arises due to developmental arrest of maturing components of the embryonic neural crest [3].

Neuroblastoma has been associated with central hypoventilation, Hirschsprung disease, and neurofibromatosis type 1 (neurocristopathy syndrome), and as a familial disorder associated with mutations in the ALK gene. These are discussed separately. (See "Epidemiology, pathogenesis, and pathology of neuroblastoma".)

The clinical presentation, diagnosis, and staging evaluation of neuroblastoma will be presented here. The epidemiology, pathogenesis, pathology, treatment, and prognosis of neuroblastoma are presented separately. (See "Epidemiology, pathogenesis, and pathology of neuroblastoma" and "Treatment and prognosis of neuroblastoma".)

                      

Subscribers log in here

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information or to purchase a personal subscription, click below on the option that best describes you:
Literature review current through: Nov 2016. | This topic last updated: Fri May 13 00:00:00 GMT+00:00 2016.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2016 UpToDate, Inc.
References
Top
  1. Goodman MT, Gurney JG, Smith MA, Olshan AF. Sympathetic nervous system tumors. In: Cancer Incidence and Survival among Children and Adolescents: United States SEER Program, 1975-1995, Ries, LA, Smith, MA, Gurney, JG, et al (Eds), National Cancer Institute, Bethesda, MD 1999. p.35.
  2. Brodeur GM, Hogarty MD, Mosse YP, Maris JM. Neuroblastoma. In: Principles and Practice of Pediatric Oncology, Pizzo PA, Poplack DG (Eds), Lippincott Williams & Wilkins, Philadelphia 2011. p.886.
  3. Louis CU, Shohet JM. Neuroblastoma: molecular pathogenesis and therapy. Annu Rev Med 2015; 66:49.
  4. Neuroblastic tumours of adrenal gland and sympathetic nervous system. In: Pathology and Genetics of Tumours of the Nervous System, World Health Organization, IARC, Lyon 2000. p.153.
  5. DuBois SG, Kalika Y, Lukens JN, et al. Metastatic sites in stage IV and IVS neuroblastoma correlate with age, tumor biology, and survival. J Pediatr Hematol Oncol 1999; 21:181.
  6. Golden CB, Feusner JH. Malignant abdominal masses in children: quick guide to evaluation and diagnosis. Pediatr Clin North Am 2002; 49:1369.
  7. Angstman KB, Miser JS, Franz WB 3rd. Neuroblastoma. Am Fam Physician 1990; 41:238.
  8. Ingram L, Rivera GK, Shapiro DN. Superior vena cava syndrome associated with childhood malignancy: analysis of 24 cases. Med Pediatr Oncol 1990; 18:476.
  9. Ogita S, Tokiwa K, Takahashi T, et al. Congenital cervical neuroblastoma associated with Horner syndrome. J Pediatr Surg 1988; 23:991.
  10. Woodruff G, Buncic JR, Morin JD. Horner's syndrome in children. J Pediatr Ophthalmol Strabismus 1988; 25:40.
  11. George ND, Gonzalez G, Hoyt CS. Does Horner's syndrome in infancy require investigation? Br J Ophthalmol 1998; 82:51.
  12. Musarella MA, Chan HS, DeBoer G, Gallie BL. Ocular involvement in neuroblastoma: prognostic implications. Ophthalmology 1984; 91:936.
  13. Mahoney NR, Liu GT, Menacker SJ, et al. Pediatric horner syndrome: etiologies and roles of imaging and urine studies to detect neuroblastoma and other responsible mass lesions. Am J Ophthalmol 2006; 142:651.
  14. LaBrosse EH, Com-Nougué C, Zucker JM, et al. Urinary excretion of 3-methoxy-4-hydroxymandelic acid and 3-methoxy-4-hydroxyphenylacetic acid by 288 patients with neuroblastoma and related neural crest tumors. Cancer Res 1980; 40:1995.
  15. Sadilkova K, Dugaw K, Benjamin D, Jack RM. Analysis of vanillylmandelic acid and homovanillic acid by UPLC-MS/MS in serum for diagnostic testing for neuroblastoma. Clin Chim Acta 2013; 424:253.
  16. Cangemi G, Barco S, Reggiardo G, et al. Interchangeability between 24-hour collection and single spot urines for vanillylmandelic and homovanillic acid levels in the diagnosis of neuroblastoma. Pediatr Blood Cancer 2013; 60:E170.
  17. Brunklaus A, Pohl K, Zuberi SM, de Sousa C. Investigating neuroblastoma in childhood opsoclonus-myoclonus syndrome. Arch Dis Child 2012; 97:461.
  18. Kaplan SJ, Holbrook CT, McDaniel HG, et al. Vasoactive intestinal peptide secreting tumors of childhood. Am J Dis Child 1980; 134:21.
  19. Funato M, Fujimura M, Shimada S, et al. Rapid changes of serum vasoactive intestinal peptide after removal of ganglioneuroblastoma with watery-diarrhea-hypokalemia-achlorhydria syndrome in a child. J Pediatr Gastroenterol Nutr 1982; 1:131.
  20. Davies RP, Slavotinek JP, Dorney SF. VIP secreting tumours in infancy. A review of radiological appearances. Pediatr Radiol 1990; 20:504.
  21. Cowie F, Corbett R, Pinkerton CR. Lung involvement in neuroblastoma: incidence and characteristics. Med Pediatr Oncol 1997; 28:429.
  22. Scott JP, Morgan E. Coagulopathy of disseminated neuroblastoma. J Pediatr 1983; 103:219.
  23. Labotka RJ, Morgan ER. Myelofibrosis in neuroblastoma. Med Pediatr Oncol 1982; 10:21.
  24. Quinn JJ, Altman AJ. The multiple hematologic manifestations of neuroblastoma. Am J Pediatr Hematol Oncol 1979; 1:201.
  25. Hawthorne HC Jr, Nelson JS, Witzleben CL, Giangiacomo J. Blanching subcutaneous nodules in neonatal neuroblastoma. J Pediatr 1970; 77:297.
  26. Lucky AW, McGuire J, Komp DM. Infantile neuroblastoma presenting with cutaneous blanching nodules. J Am Acad Dermatol 1982; 6:389.
  27. Wyatt AJ, Hansen RC. Pediatric skin tumors. Pediatr Clin North Am 2000; 47:937.
  28. Ho PT, Estroff JA, Kozakewich H, et al. Prenatal detection of neuroblastoma: a ten-year experience from the Dana-Farber Cancer Institute and Children's Hospital. Pediatrics 1993; 92:358.
  29. Jennings RW, LaQuaglia MP, Leong K, et al. Fetal neuroblastoma: prenatal diagnosis and natural history. J Pediatr Surg 1993; 28:1168.
  30. Acharya S, Jayabose S, Kogan SJ, et al. Prenatally diagnosed neuroblastoma. Cancer 1997; 80:304.
  31. Holgersen LO, Subramanian S, Kirpekar M, et al. Spontaneous resolution of antenatally diagnosed adrenal masses. J Pediatr Surg 1996; 31:153.
  32. Fénart D, Deville A, Donzeau M, Bruneton JN. [Retroperitoneal neuroblastoma diagnosed in utero. Apropos of 1 case]. J Radiol 1983; 64:359.
  33. Wilson PE, Oleszek JL, Clayton GH. Pediatric spinal cord tumors and masses. J Spinal Cord Med 2007; 30 Suppl 1:S15.
  34. Pranzatelli MR. The neurobiology of the opsoclonus-myoclonus syndrome. Clin Neuropharmacol 1992; 15:186.
  35. Averbuch-Heller L, Remler B. Opsoclonus. Semin Neurol 1996; 16:21.
  36. Wilfong AA, Parke JT, McCrary JA 3rd. Opsoclonus-myoclonus with Beckwith-Wiedemann syndrome and hepatoblastoma. Pediatr Neurol 1992; 8:77.
  37. Verma A, Brozman B. Opsoclonus-myoclonus syndrome following Epstein-Barr virus infection. Neurology 2002; 58:1131.
  38. Sheth RD, Horwitz SJ, Aronoff S, et al. Opsoclonus myoclonus syndrome secondary to Epstein-Barr virus infection. J Child Neurol 1995; 10:297.
  39. Vukelic D, Bozinovic D, Morovic M, et al. Opsoclonus-myoclonus syndrome in a child with neuroborreliosis. J Infect 2000; 40:189.
  40. McCarthy VP, Zimmerman AW, Miller CA. Central nervous system manifestations of parainfluenza virus type 3 infections in childhood. Pediatr Neurol 1990; 6:197.
  41. Adamolekun B, Hakim JG. Opsoclonus-myoclonus associated with traditional medicine ingestion: case report. East Afr Med J 1998; 75:120.
  42. Scharf D. Opsoclonus-myoclonus following the intranasal usage of cocaine. J Neurol Neurosurg Psychiatry 1989; 52:1447.
  43. Matsumura K, Sonoh M, Tamaoka A, Sakuta M. Syndrome of opsoclonus-myoclonus in hyperosmolar nonketotic coma. Ann Neurol 1985; 18:623.
  44. Kuban KC, Ephros MA, Freeman RL, et al. Syndrome of opsoclonus-myoclonus caused by Coxsackie B3 infection. Ann Neurol 1983; 13:69.
  45. Brodeur GM, Pritchard J, Berthold F, et al. Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. J Clin Oncol 1993; 11:1466.
  46. Corrigan JJ, Feig SA, American Academy of Pediatrics. Guidelines for pediatric cancer centers. Pediatrics 2004; 113:1833.
  47. Monclair T, Brodeur GM, Ambros PF, et al. The International Neuroblastoma Risk Group (INRG) staging system: an INRG Task Force report. J Clin Oncol 2009; 27:298.
  48. Cohn SL, Pearson AD, London WB, et al. The International Neuroblastoma Risk Group (INRG) classification system: an INRG Task Force report. J Clin Oncol 2009; 27:289.
  49. Vik TA, Pfluger T, Kadota R, et al. (123)I-mIBG scintigraphy in patients with known or suspected neuroblastoma: Results from a prospective multicenter trial. Pediatr Blood Cancer 2009; 52:784.
  50. Shulkin BL, Shapiro B. Current concepts on the diagnostic use of MIBG in children. J Nucl Med 1998; 39:679.
  51. Perel Y, Conway J, Kletzel M, et al. Clinical impact and prognostic value of metaiodobenzylguanidine imaging in children with metastatic neuroblastoma. J Pediatr Hematol Oncol 1999; 21:13.
  52. Geatti O, Shapiro B, Sisson JC, et al. Iodine-131 metaiodobenzylguanidine scintigraphy for the location of neuroblastoma: preliminary experience in ten cases. J Nucl Med 1985; 26:736.
  53. Voute PA, Hoefnagel CA, Marcuse HR, de Kraker J. Detection of neuroblastoma with 131I-meta-iodobenzylguanidine. Prog Clin Biol Res 1985; 175:389.
  54. Taggart DR, Han MM, Quach A, et al. Comparison of iodine-123 metaiodobenzylguanidine (MIBG) scan and [18F]fluorodeoxyglucose positron emission tomography to evaluate response after iodine-131 MIBG therapy for relapsed neuroblastoma. J Clin Oncol 2009; 27:5343.
  55. van Santen HM, de Kraker J, van Eck BL, et al. High incidence of thyroid dysfunction despite prophylaxis with potassium iodide during (131)I-meta-iodobenzylguanidine treatment in children with neuroblastoma. Cancer 2002; 94:2081.
  56. Picco P, Garaventa A, Claudiani F, et al. Primary hypothyroidism as a consequence of 131-I-metaiodobenzylguanidine treatment for children with neuroblastoma. Cancer 1995; 76:1662.
  57. Garaventa A, Guerra P, Arrighini A, et al. Treatment of advanced neuroblastoma with I-131 meta-iodobenzylguanidine. Cancer 1991; 67:922.
  58. van Santen HM, de Kraker J, van Eck BL, et al. Improved radiation protection of the thyroid gland with thyroxine, methimazole, and potassium iodide during diagnostic and therapeutic use of radiolabeled metaiodobenzylguanidine in children with neuroblastoma. Cancer 2003; 98:389.
  59. Kaufman RA, Thrall JH, Keyes JW Jr, et al. False negative bone scans in neuroblastoma metastatic to the ends of long bones. AJR Am J Roentgenol 1978; 130:131.
  60. Schilling FH, Spix C, Berthold F, et al. Neuroblastoma screening at one year of age. N Engl J Med 2002; 346:1047.
  61. Yamamoto K, Ohta S, Ito E, et al. Marginal decrease in mortality and marked increase in incidence as a result of neuroblastoma screening at 6 months of age: cohort study in seven prefectures in Japan. J Clin Oncol 2002; 20:1209.
  62. Woods WG, Gao RN, Shuster JJ, et al. Screening of infants and mortality due to neuroblastoma. N Engl J Med 2002; 346:1041.
  63. Kerbl R, Urban CE, Ambros IM, et al. Neuroblastoma mass screening in late infancy: insights into the biology of neuroblastic tumors. J Clin Oncol 2003; 21:4228.
  64. Oue T, Inoue M, Yoneda A, et al. Profile of neuroblastoma detected by mass screening, resected after observation without treatment: results of the Wait and See pilot study. J Pediatr Surg 2005; 40:359.
  65. Nuchtern JG, London WB, Barnewolt CE, et al. A prospective study of expectant observation as primary therapy for neuroblastoma in young infants: a Children's Oncology Group study. Ann Surg 2012; 256:573.